Mechanisms of white matter damage in multiple sclerosis

GLIA

Volumn 62, Issue 11, 2014, Pages 1816-1830

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Astrocytes; Demyelination; Microglia; Multiple sclerosis; Oligodendrocytes

Indexed keywords

IRON; MYELIN PROTEIN;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ASTROCYTE; AUTOIMMUNITY; CELL ACTIVATION; CELL DAMAGE; DEMYELINATION; DISEASE COURSE; ENCEPHALITIS; EXPERIMENTAL MODEL; GLIA CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; REMYELINIZATION; REVIEW; TISSUE INJURY; WHITE MATTER; ANIMAL; COMPLICATION; GLIA; METABOLISM; PATHOLOGY; WHITE MUSCLE DISEASE;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; MYELIN PROTEINS; NEUROGLIA; WHITE MUSCLE DISEASE;

EID: 84912567915     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22597     Document Type: Review

References (163)

1. Aboul-Enein F, Rauschka H, Kornel B, Stadelmann C, Stefferl A, Brück W, Lucchinetti CF, Schmidbauer M, Jellinger K, Lassmann H. 2003. Preferential loss of myelin associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropath Exp Neurol 62:25-33.
2. Albert M, Antel J, Brück W, Stadelmann C. 2007. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 17:129-138.
3. Amolda B, Gonzales B, Castellano B. 2011. Antigen presentation in EAE: Role of microglia, macrophages and dendritic cells Front Biosci 16:1157-1171
4. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S. 2010. Meningeal T-cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 68:465-476.
5. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192:393-404.
6. Babinski J. 1885. Recherches sur l'anatomie pathologique de la sclerose en plaque et etude comparative des diverses varietes de la scleroses de la moelle. Arch Physiol (Paris) 5-6:186-207.
7. Bagnato F, Hametner S, Yao B, van Gelderen P, Merkle H, Cantor FK, Lassmann H, Duyn JH. 2011. Tracking iron in multiple sclerosis: A combined imaging and histopathological study at 7 Tesla. Brain 134:3602-3615.
8. Bajramovic JJ, Lassmann H, VanNoort JM. 1997. Expression of alphaB-crystallin in glia cells during lesional development in multiple sclerosis. J Neuroimmunol 78:143-151.
9. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55:458-468.
10. Barnett SC, Linington C. 2013. Myelination: Do astrocytes play a role? Neuroscientist 19:442-450.
11. Bizzozero OA, Dejesus G, Callaha K, Pastuszyn A. 2005. Elevated protein carbonylation in the brain white matter and grey matter of patients with multiple sclerosis. J Neurosci Res 81:687-695.
12. Bhat R, Crowe EP, Bitto A, Moh M, Katsetos CD, Garcia FU, Johnson FB, Trojanowski JQ, Sell C, Torres C. 2012. Astrocyte senescence as a component of Alzheimer's disease. PLoS One 7:e45069.
13. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. 2003. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropath Exp Neurol 62:723-732.
14. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD. 2006. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129:517-526.
15. Bradl M, Lassmann H. 2010. Oligodendrocytes: biology and pathology. Acta Neuropathologica 119:37-53.
16. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, Laursen H. 2010. Demyelination versus remyelination in progressive multiple sclerosis. Brain 133:2983-2998.
17. Breij ECW, Brink BP, Veerhuis R, Van den Berg C, Vloer R, Yan R, Dijkstra CD, Van der Valk P, Bo L. 2008. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63:16-25.
18. Breithaupt C, Schäfer B, Pellkofer H, Huber R, Linington C, Jacob U. 2008. Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody responses is focused on one dominant conformational epitope region in rodents. J Immunol 181:1255-1263.
19. Brink BP, Veerhuis R, Breij EC, Van der Valk P, Dijkstra CD, Bo L. 2005. The pathology of multiple sclerosis is location dependent: No significant complement activation is detected in purely cortical lesions. J Neuropath Exp Neurol 64:147-155.
20. Brosnan CF, Raine CS. 2013. The astrocyte in multiple sclerosis revisited. Glia 61:453-465.
21. Brück W, Pförtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, Hanisch UK, Regen T, Van Rossum D, Brakelmann L, Hagemeier K, Kuhlmann T, Stadelmann C, John GR, Kramann N, Wegner C. 2012. Reduced astrocytic NF-kB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol (Berl) 124:411-424.
22. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H. 1995. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38:788-796.
23. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, Lassmann H, Turnbull DM, Mahad DF. 2010. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 69:481-492.
24. Chang A, Tourtelotte WW, Rudick R, Trapp BD. 2002. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346:165-173.
25. Charles P, Reynolds R, Seilhean D, Rougon G, Aigrot MS, Niezgoda A, Zalc B, Lubstzki C. 2002. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain 125:1972-1979.
26. e ed. Paris.
27. Choi S, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, Nicholas R, Roncaroli F, Reynolds R. 2012. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135:2925-2937.
28. Coleman M. 2005. Axon degeneration mechanisms: commonality and diversity. Nat Rev Neurosci 6:889-898.
29. Connor JR. 2013. Iron and glia. In: Kettenmann H, Ransom BR, editors. Neuroglia. Oxford University Press, New York; pp 586-602.
30. Craelius W, Migdal MW, Luessenhop P, Sugar A, Mihalakis I. 1982. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 106:397-399.
31. Cui QL, Kuhlmann T, Miron VE, Leong SY, Fang J, Gris P, Kennedy TE, Almazan G, Antel J. 2013. Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis. Am J Pathol 183:516-525.
32. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. 2011. The relevance of animal models in multiple sclerosis research. Pathophysiology 18: 21-29.
33. de Vries HE, Witte ME, Hondius D, Rozemuller A, Drukarch B, Hoozemans J, Van Horssen J. 2008. Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease. Free Radic Biol Med 45:1375-1383.
34. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD. 2006. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478-489.
35. Esiri MM. 1980. Multiple sclerosis: A quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropath Appl Neurobiol 6:9-21.
36. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. 2001. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124:1813-1820.
37. Ferguson B, Matyszak MK, Esiri MM, Perry VH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399.
38. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, Van Horssen J, Lassmann H. 2012. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135:886-899.
39. Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, Zrzavy T, Hametner S, Mahad D, Binder CJ, Krumbholz M, Bauer J, Bradl M, Lassmann H. 2013. Disease-specific molecular events in cortical multiple sclerosis lesions Brain 136:1799-1815.
40. + T cells in multiple sclerosis: A new target for therapy? Brain 128:1747-1763.
41. Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon RM, Jensen LT, Huygelen V, Jones EY, Bell JI, Fugger L. 2008. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T-cells in multiple sclerosis. Nat Med 14:1227-1235.
42. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. 2009. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175-1189.
43. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzyetanova ID, Möbius W, Diaz F, Meier D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Frahm J, Goebbels S, Nave KA. 2012. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485:517-521.
44. Genain CP, Cannella B, Hauser SL, Raine CS. 1999. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-175.
45. Gold R, Linington C, Lassmann . 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Part 8):1953-1971.
46. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. 2012. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098-1107.
47. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. 2008. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett 442:195-198.
48. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. 2010. Laquinimod supress antigen presentation in relapsing-remitting multiple sclerosis: In vitro high-throughput gene expression study. J Neuroimmunol 221:87-94.
49. Gveric D, Kaltschmidt C, Cuzner ML, Newcombe J. 1998. Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol 57:168-178.
50. Hagg T, Oudega M. 2006. Degenerative and spontaneous regenerative processes after spinal cord trauma. J Neurotrauma 23:264-280.
51. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. 2011. Oxidative damage in multiple sclerosis lesions. Brain 134:1914-1924.
52. Hallgren B, Sourander P. 1958. The effect of age on the non-haemin iron in the human brain. J Neurochem 3:41-51.
53. Hametner S, Wimmer I, Haider L, Pfeiffenbring S, Brück W, Lassmann H. 2013. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 74:848-861.
54. Harding AE, Sweeney MG, Miller DH, Mumford CJ, Kellar-Wood H, Menard D, McDonald WI, Compston DA. 1992. Occurrence of a multiple sclerosis like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 115:979-989.
55. Hendrickx DA, Koning N, Schuurman KG, Van Strien ME, Van Eden CG, Hamann J, Huitinga I. 2013. Selective upregulation of scavenger receptors in and around demyelinating areas in multiple sclerosis. J Neuropath Exp Neurol 72:106-118.
56. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, Howe CL, Pittock SJ, Lennon VA. 2008. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 205:2437-2481.
57. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, Korosec T, Kutzelnigg A, Berger JJ, Bradl M, Bittner RE, Lassmann H. 2006. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65:855-865.
58. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, Serafini B, Aloisi F, Roncaroli F, Magliozzi R, Reynolds R. 2011. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134:2755-2771.
59. + T-cells in a model for multiple sclerosis. J Exp Med 194:669-676.
60. Jack C, Ruffini F, Bar Or A, Antel JP. 2005. Microglia and multiple sclerosis. J Neurosci Res 81:363-373.
61. Jakob A. 1915. Zur Pathogenese der diffusen infiltrativen Enzephalomyelitis in ihren Beziehungen zur diffusen und multiplen Sklerose. Z ges Neurol Psychiat 27:290-320.
62. Kidd T, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. 1999. Cortical lesions in multiple sclerosis. Brain 122:17-26.
63. Kolasinski J, Stagg CJ, Chance SA, DeLuca GC, Esiri MM, Chang EH, Palace JA, McNab JA, Jenkinson M, Miller KL, Johansen-Berg H. 2012. A combined post-mortem MRI and quantitative histological study of multiple sclerosis pathology. Brain 135:2938-2951.
64. Kovacs GG, Höftberger R, Majtenyi K, Barsi P, Komoly S, Lassmann H, Budka H, Jakab G. 2005. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 128:35-41.
65. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Brück W. 2009. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749-1758.
66. Kuhlmann T, Lassmann H, Brück W. 2008. Diagnosis of inflammatory demyelination in biopsy specimens: A practical approach. Acta Neuropathol 115:275-287.
67. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. 2005. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-2712.
68. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H. 2007. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 17:38-44.
69. Lassmann H, Van Horssen J, Mahad D. 2012. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol 8:647-656.
70. Lassmann H. 2011. Review: The architecture of inflammatory demyelinating lesions: Implications for studies on pathogenesis. Neuropathol Appl Neurobiol 37:698-710.
71. Lassmann H, Brück W, Lucchinetti C. 2007. The immunopathology of multiple sclerosis: An overview. Brain Pathol 17:210-218.
72. Lin W, Popko B. 2009. Endoplasmic reticulum stress in disorders of myelinating cells. Nat Neurosci 12:379-385.
73. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454.
74. Linker RA, Lee DH, Ryan S, Van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Brück W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R. 2011. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 3:678-692.
75. Lisak RP, Benjamins JA, Bealmear B, Nedelkoska L, Studzinski D, Retland E, Yao B, Land S. 2009. Differential effects of Th1, monocyte/macrophage and Th2 cytokin mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures. J Neuroinflammation 6:4.
76. Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A. 2012. Secretry products of multiple sclerosis B-cells are cytotoxic to oligodendrocytes in vitro. J Neuroimmunol 246:85-95.
77. Liu JSH, Zhao ML, Brosnan CF, Lee SC. 2001. Expression of indicible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 158:2057-2066.
78. Lopes KO, Sparks DL, Streit WJ. 2008. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 56:1048-1060.
79. Lu F, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C, Kalman B. 2000. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 177:95-103.
80. Lublin FD, Reingold SC. 1996. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911.
81. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals Neurol 47:707-717.
82. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 1999. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 117 cases. Brain 122:2279-2295.
83. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365:2188-2197.
84. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopoplo M, Reynolds R, Aloisi F. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089-1104.
85. Mahad D, Ziabreva I, Lassmann H, Turnbull D. 2008. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131:1722-1735.
86. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM. 2009. Mitochondrial changes within axons in multiple sclerosis. Brain 132:1161-1174.
87. Markoulis K, Sargiannidou I, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, Kleopa KA. 2012. Gap junction pathology in multiple sclerosis and normal appearing white matter. Acta Neuropathol 123:873-886.
88. Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, Cavillon G, Rogemond V, Confavreux C, Honnorat J, Giraudon P. 2010. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 133:2578-2591.
89. Marik C, Felts P, Bauer J, Lassmann H, Smith KJ. 2007. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130:2800-2815.
90. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C. 2007. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204:2363-2372.
91. Matsuoka T, Suzuki SO, Iwaki T, Tabira T, Ordinario AT, Kira J. 2010. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120:651-680.
92. Matsushima GK, Morell P. 2001. The neurotoxicant, #cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116.
93. Matsushita T, Masaki K, Suzuki S, Matsuoka T, Yonekawa T, Wu XM, Tabira T, Iwaki T, Kira J. 2011. Astrocytopathy in neuromyelitis optica, multiple sclerosis and Balo's disease. Rinsho Shinkeigaku 51:898-900.
94. Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadelmann C. 2006. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129:1972-1983.
95. Misu T, Höftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Nakashima I, Konno H, Bradl M, Garzuly F, Itoyama Y, Aoki M, Lassmann H. 2013. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 125:815-827.
96. Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. 2009. Fumaric acid and its esters: An emerging treatment for multiple sclerosis. Curr Neuropharmacol 7:60-64.
97. Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RH. 2008. Cortical demyelination in PML and MS: Similarities and differences. Neurology 70:336-343.
98. Moore CS, Abdullah SL, Brown A, Arulpragasam A, Crocker SJ. 2011. How factors secreted from astrocytes impair myelin repair. J Neurosci Res 89:13-21.
99. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417:1-13.
100. Na SY, Cao Y, Toben C, Nitschke L, Stadelmann C, Gold R, Schimpl A, Hünig T. 2008. Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 131:2353-2365.
101. Na SY, Hermann A, Snachez-Ruiz M, Storch A, Deckert M, Hünig T. 2012. Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoactive CD8+ T cells. Immunity 37:134-146.
102. Nair A, Frederick TJ, Miller SD. 2008. Astrocytes in multiple sclerosis: A product of their environment. Cell Mol Life Sci 65:2702-2720.
103. Neumann H, Kotter MR, Franklin RJ. 2009. Debris clearance by microglia: An essential link between degeneration and regeneration. Brain 132:288-295.
104. Neumann H, Medana I, Bauer J, Lassmann H. 2002. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25:313-319.
105. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Keutzfeldt M, Bareyre FM, Brück W, Bishop D, Misgeld T, Kerschensteiner M. 2011. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 17:495-499.
106. Nimmagadda VK, Bever CT, Vattikunta NR, Talat S, Ahmad V, Nagalla NK, Trisler D, Judge SI, Royal W, Chandrasekaran K, Russell JW, Makar TK. 2013. Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J Immunol 190:4595-4607.
107. Owens T. Immune functions of microglia. 2013. In: Kettenmann H, Ransom BR, editors. Neuroglia. Oxford University Press, New York. pp 638-652.
108. Ozawa K, Suchanek G, Breitschopf H, Brück W, Budka H, Jellinger K, Lassmann H. 1994. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:1311-1322.
109. Pantoni L, Garcia JH, Gutierrez JA. 1996. Cerebral white matter is highly vulnerable to ischemia. Stroke 27:1641-1646.
110. Parratt JD, Prineas JW. 2010. Neuromyelitis optica: A demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 16:1156-1172.
111. Patani R, Balaratnam M, Vora A, Reynolds R. 2007. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropath Appl Neurobiol 33:277-287.
112. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorenson PS, Brück W, Lucchinetti C, Lassmann H. 2006. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165-3172.
113. Perry VH, Nicoll JA, Holmes C. 2010. Microglia in neurodegenerative disease. Nat Rev Neurol 6:193-201.
114. Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, Rammohan K, Knopp MV, Schmalbrock P. 2010. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 67:812-818.
115. Prineas JW 1985. The neuropathology of multiple sclerosis. In: Koetsier JC, editor. Handbook of clinical neurology. Vol 47, Elsevier: New York, pp 337-395.
116. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP. 2001. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50:646-657.
117. Prineas, JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. 1993a. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33:137-151.
118. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. 1993b. Multiple sclerosis. Pathol Recurrent Lesions. Brain 116: 681-693.
119. Prineas JW, Kwon EE, Goldenberg PZ, Ilyas AA, Quarles RH, Benjamins JA, Sprinkle TJ. 1989. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 61:489-503.
120. Raine CS, Scheinberg L, Waltz JM. 1981. Multiple sclerosis: Oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 45:534-546.
121. Raine CS, Wi E, Ivani J, Katz D, Brosnan CF. 1996. Multiple sclerosis: A protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 75:109-123.
122. Ramaglia V, Hughes TR, Donev RM, Ruseva MM, Wu X, Huitinga I, Baas F, Neal JW, Morgan BP. 2012. C3-dependent mechanism of microglia priming relevant to multiple sclerosis. Proc Natl Acad Sci USA 109:965-970.
123. Rathore KI, Kerr BJ, Redensek A, Lopez-Vales R, Jeong SY, Ponka P, David S. 2008. Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage. J Neurosci 28:12736-12747.
124. Rice CM, Sun M, Kemp K, Gray E, Wilkins A, Scolding NJ. 2012. Mitochondrial sirtuins-A new therapeutic target for repair and protection in multiple sclerosis. Eur J Neurosci 35:1887-1893.
125. Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, Karenfort M, Tibussek D, Blaschek A, Bajer-Kornek B, Leitz S, Schimmel M, Di Pauli F, Berger T, Reindl M. 2012. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 69:752-756.
126. Saxena A, Bauer J, Scheikl T, Zappulla J, Audebert M, Desbois S, Waisman A, Lassmann H, Liblau RS, Mars LT. 2008. Cutting edge: Multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes. J Immunol 181:1617-1621.
127. Schulz K, Vulpe CD, Harris LZ, David S. 2011. Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J Neurosci 31:13301-13311.
128. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164-174.
129. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, Fujihara K, Bradl M, Lassmann H. 2010. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 120:223-236.
130. Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. 2007. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophtalmol Vis Sci 48:3602-3609.
131. Singh S, Metz I, Amor S, Van der Valk P, Stadelmann C, Brück W. 2013. Microglial nodules in early multiple sclerosis white matter are asscociated with degenerating axons. Acta Neuropathol 125:595-608.
132. Smith KJ, Kapoor PA, Felts PA. 1999. Demyelination: The role of reactive oxygen and nitrogen species. Brain Pathol 9:69-92.
133. Sofroniew MV, Vinters HV. 2010. Astrocytes; biology and pathology. Acta Neuropathol 119:7-35.
134. Sofroniew MV. 2013. Astrocyte responses to central nervous system injury. In: Kettenmann H, Ransom BR, editors. Neuroglia. Oxford University Press, pp 653-664.
135. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennet JL, Korn T, Hemmer B. 2012. Potassium channel KIR4.1 as an immune target in multiple sclerosis. New Engl J Med 367:115-123.
136. Stahnke T. Stadelmann C, Netzler A, Brück W, Richter-Landsberg C. 2007. Differential up-regulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci 32:25-37.
137. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, Olsson T, Linington C, Lassmann H. 1998. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694.
138. Storch MK, Bauer J, Linington C, Olsson T. Weissert R, Lassmann H. 2006. Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatibility complex (MHC) haplotype-related. J Neuropathol Exp Neurol 65:1137-1142.
139. Su K, Bourdette D, Forte M. 2012. Genetic inactivation of mitochondria-targeted redox enzyme p66ShcA preserves neuronal viability and mitochondrial integrity in response to oxidative challenges. Front Physiol 3:285.
140. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS. 2001. Myelin antigen specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 166:7579-7587.
141. Trapp BD, Stys PK. 2009. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 8:280-291.
142. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, Selleberg F, Lassmann H, Ransohoff RM. 2001. CCR1+/CCR5+ mononuclear phagocytes accumulat in the central nervous system of patients with multiple sclerosis. Am J Pathol 159:1701-1710.
143. Van der Star BJ, Vogel DY, Kipp M, Puentes F, Baker D, Amor S. 2012. In virto and in vivo models of multiple sclerosis. CNS Neurol Disord Drug Targets 11:570-588.
144. Van der Valk P, Amor S. 2009. Preactive lesions in multiple sclerosis. Curr Opin Neurol 22:207-213.
145. Van Horssen J, Singh S, Van der Pol S, Kipp M, Lim JL, Gerritsen W, Kooi EJ, Witte ME, Geurts JJ, de Vries HE, Peferoen-Baert R, Van der Elsen PJ, Van der Valk P. Amor S. 2012. Clusters of activated microglia in normal appearing white matter show signs of innate immune activation. J Neuroinflammation 9:156.
146. van Horssen J, Drexhage J, Flor T, Gerritsen W, Van der Valk P, de Vries HE. 2010. Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 8:1283-1289.
147. Van Horssen J, Schreibelt G, Bö L, Montagne L, Drukarch B, Van Muiswinkel FL, de Vries HE. 2006. NADPH:qionone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic Biol Med 41:311-317.
148. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, Van der Valk P, de Vires . 2008. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biol Med 45:1729-1737.
149. Van Horssen J, Witte ME, Schreibelt G, de Vries HE. 2011. Radical changes in multiple sclerosis pathogenesis. Biochem Biophys Acta 1812:141-150.
150. Van Noort JM, Van der Elsen PJ, Van Horssen J, Geurts JJ, Van der Valk P, Amor S. 2011. Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies. CNS Neurol Disord Drug Targets 10:68-81.
151. Vass K, Lassmann H. 1990. Intrathecal application of interferon gamma progressive appearance of MHC antigens within the rat nervous system. Am J Pathol 137:789-800.
152. Veto S, Acs P, Bauer J, Lassmann H, Berente Z, Setalo G Jr, Borgulya G, Sumegi B, Komoly S, Gallyas F Jr, Illes Z. 2010. Inhibiting poly(ADP-ribose) polymerase: A potential therapy against oligodendrocyte death. Brain 133:822-834.
153. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, Van der Valk P, Amor S, Teunissen CE, Van Horssen J, Dijkstra CD. 2013. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation 19:35.
154. Von Büdingen HC, Hauser SL, Fuhrmann A, Nabavi CB, Lee JI, Genain CP. 2002. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci USA 99:8207-8212.
155. Williams R, Buchheit CL, Berman NE, LeVine SM. 2012. Pathogenic implications of iron accumulation in multiple sclerosis. J Neurochem 120:7-25.
156. Williams A, Piaton G, Lubetzki C. 2007a. Astrocytes-Friends or foes in multiple sclerosis? Glia 55:1300-1312.
157. Williams A, Piaton G, Aigrot MS, Belhadi A, Theaudin M, Petermann F, Thomas JL, Zalc B, Lubstzki C. 2007b. Semaphorins 3A and 3F: Key players in myelin repair in multiple sclerosis. Brain 130:2554-2565.
158. Witte ME, Bo L, Rodenburg R, Belien JA, Musters R, Hazes T, Wintjes L, Smeitink JA, Geurts JJ, de Vries HE, Van der Valk P, Van Horssen J. 2009. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2:193-204.
159. Wu E, Raine CS. 1992. Multiple sclerosis. Interactions between oligodendrocytes and hypertrophic astrocytes and their occurrence in other, #non demyelinating conditions. Lab Invest 67:88-99.
160. Wolswijk G. 2000. Oligodendrocyte survival, #loss and birth in lesions of chronic multiple sclerosis. Brain 123:105-115.
161. Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, Chen J. 2011. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol 95:373-395.
162. Zeis T, Propst A, Steck AJ, Stadelmann C, Brück W, Schaeren-Wiemers N. 2009. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol 19:459-466.
163. Ziabreva I, Campbell G, Rist J, Zambonin J, Rorbach J, Wydro MM, Lassmann H, Franklin RJ, Mahad D. 2010. Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes. Glia 58:1827-1837.